https://www.selleckchem.com/products/ru58841.html
Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes and are becoming a standard treatment for many cancer types. However, these drugs also induce immune-related adverse events, among which interstitial lung disease (ILD) is potentially fatal. The underlying mechanism of ILD induction by ICIs is largely unknown. With the use of flow cytometry, we determined the expression levels of the immune-checkpoint proteins PD-1, TIM-3, TIGIT, LAG-3, and PD-L1 in T cells of bronchoalveolar lavage fluid (BALF) from patients with ICI-r
Like
Comment
Share
